Back to Authors

Fox, John

Mayo Clinic

Mayo Clinic

Citations 2

Homologous amino-terminal radioimmunoassay for rat parathyroid hormone
Calvo, Mona S. , Gundberg, Caren M., Heath, Hunter, Fox, John

American Journal of Physiology-Endocrinology and Metabolism | December 21, 2017 | Volume: 261 | Issue: 2 | Pages: E262-E268

10.1152/ajpendo.1991.261.2.e262 Get It

Existing radioimmunoassays for parathyroid hormone (PTH) in rat plasma are based on cross-reactivity of rat PTH (rPTH) with heterologous antisera. We used the synthetic NH2-terminal fragment of rPTH [rPTH-(1-34)] to develop a homologous radioimmunoassay for circulating PTH. An antiserum to rPTH-(1-34) was raised in a goat (G-813), and the same peptide was used as radioligand (125I) and standard. Purification of the label by high-performance liquid chromatography (HPLC) increased specific binding greater than twofold and sensitivity by 50-100%. With a final antiserum dilution of 1:70,000, maximum specific binding of 30-33%, nonspecific binding of 1-5%, and 50-microliters sample additions, the assay detection limit was 1.8-2.5 pmol/l. A midregional fragment of human PTH did not displace 125I-labeled rPTH-(1-34). HPLC of extracts of rat parathyroid glands and hyperparathyroid plasma showed only a single peak of immunoreactivity that eluted 2 min after rPTH-(1-34). Dose dilution curves for rat parathyroid gland extracts, rPTH-(1-34) added to rat plasma, and endogenous rat plasma PTH all paralleled the standard curve. Immunoreactive PTH (irPTH) was detectable in greater than 90% of fasting normal rat plasma and changed appropriately in response to hyper- and hypocalcemia induced by low-calcium and vitamin D-deficient diets, injections of calcium and EDTA, and after thyroparathyroidectomy. The normal range for rat plasma irPTH was less than 2.0-12 pmol/l, in general agreement with bioassay results of others. Thus rPTH-(1-34) is an excellent immunogen for raising antisera to rPTH, and assays incorporating it may be of great value in studying rat parathyroid physiology.
Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research
Bilezikian, John P. , Khan, Aliya , Potts, John T. , Shoback, Dolores , Jüppner, Harald , D'Amour, P, Fox, John, Rejnmark, Lars , Mosekilde, Leif , Rubin, Mishaela R. , Gafni, Rachel I. , Sliney, J., Sanders, James M. , Brandi, Maria Luisa , Clarke, B.L. , Dempster, David W. , Collins, Michael Terrence , Rejnmark, Lars

Journal of Bone and Mineral Research | August 2, 2011 | Volume: 26 | Issue: 10 | Pages: 2317-2337

10.1002/jbmr.483 Get It

Abstract Recent advances in understanding the epidemiology, genetics, diagnosis, clinical presentations, skeletal involvement, and therapeutic approaches to hypoparathyroidism led to the First International Workshop on Hypoparathyroidism that was held in 2009. At this conference, a group of experts convened to discuss these issues with a view towards a future research agenda for this disease. This review, which focuses primarily on hypoparathyroidism in the adult, provides a comprehensive summary of the latest information on this disease. © 2011 American Society for Bone and Mineral Research